Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs

European Journal of Pharmacology

Volumn 350, Issue 1, 1998, Pages 87-91

  Sato, Kazuo ^a   Kawasaki, Tomihisa ^a   Hisamichi, Nami ^a   Taniuchi, Yuta ^a   Hirayama, Fukushi ^a   Koshio, Hiroyuki ^a   Ichihara, Masato ^a   Matsumoto, Yuzo ^a  

^a Inst for Drug Discovery Research   (Japan)

Author keywords

Arterial thrombosis; Bleeding time; Factor Xa inhibitor; Venous thrombosis; YM 60828

Indexed keywords

[N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPTHYL)METHYL]SULFAMOYL]ACETIC ACID; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; GUINEA PIG; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOSIS; VEIN THROMBOSIS;

ANIMALS; ANTITHROMBIN III; ARTERIOVENOUS SHUNT, SURGICAL; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CAROTID ARTERY, INTERNAL; DISEASE MODELS, ANIMAL; FACTOR XA; FIBRINOLYTIC AGENTS; GUINEA PIGS; MALE; NAPHTHALENES; PIPERIDINES; THROMBOPHLEBITIS; THROMBOSIS;

EID: 0032577589     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00328-8     Document Type: Article

References (16)

1. Berndt M.C., Gregory C., Dowden G., Castaldi P.A. Thrombin interactions with platelet membrane proteins. Ann. N.Y. Acad. Sci. 485:1986;374-386.
2. Elódi S., Varadi K. Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation. Thromb. Res. 15:1979;617-629.
3. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74:1995;635-639.
4. Herbert J.M., Bernat A., Dol F., Herault J.P., Crepon B., Lormeau J.C. DX-9065a a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 276:1996;1030-1038.
5. Higgins D.L., Lewis S.D., Shafer J.A. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J. Biol. Chem. 258:1983;9276-9282.
6. Lefkovits J., Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 90:1994;1522-1536.
7. MacDonald J.D., Remington B.J., Rodgers G.M. The skin bleeding time test as a predictor of brain bleeding time in a rat model. Thromb. Res. 76:1994;535-540.
8. Mellott M.J., Holahan M.A., Lynch J.J., Vlasuk G.P., Dunwiddie C.T. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ. Res. 70:1992;1152-1160.
9. Neeper M.P., Waxman L., Smith D.E., Schulman C.A., Sardana M., Ellis R.W., Schaffer L.W., Siegl P.K., Vlasuk G.P. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. J. Biol. Chem. 265:1990;17746-17752.
10. Peters R.F., Lees C.M., Mitchell K.A., Tweed M.F., Talbot M.D., Wallis R.B. The characterization of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb. Haemost. 65:1991;268-274.
11. Reyers I., Mussoni L., Donati M.B., de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb. Res. 18:1980;669-674.
12. Rosenberg J.S., Beeler D.L., Rosenberg R.D. Activation of human prothrombin by highly purified human factors V and Xa in presence of human antithrombin. J. Biol. Chem. 250:1975;1607-1617.
13. Roux S., Carteaux J.P., Hess P., Falivene L., Clozel J.P. Experimental carotid thrombosis in the guinea pig. Thromb. Haemost. 71:1994;252-256.
14. Sato K., Kawasaki T., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur. J. Pharmacol. 339:1997;141-146.
15. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. Pharmacol. 123:1998;92-96.
16. Taniuchi, Y., Sakai, Y., Hisamichi, N., Kayama, M., Mano, Y., Sato, K., Hirayama, F., Koshio, H., Matsumoto, Y., Kawasaki, T., 1998. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb. Haemost., in press.